This database contains 160 studies, archived under the term: "Background"
Click here to filter this large number of results.
Use of the Tailored Activities Program to reduce neuropsychiatric behaviors in dementia: an Australian protocol for a randomized trial to evaluate its effectiveness
O'Connor, C. M.,
Clemson, L.,
Brodaty, H.,
Jeon, Y. H.,
Mioshi, E.,
Gitlin, L. N.
Background: Behavioral and psychological symptoms of dementia (BPSD) are often considered to be the greatest challenge in dementia care, leading to increased healthcare costs, caregiver burden, and placement into care facilities. With potential for pharmacological intervention to exacerbate behaviors or even lead to mortality, the development and rigorous testing of non-pharmacological interventions is vital. A […]
Effects of SolCos model-based individual reminiscence on older adults with mild to moderate dementia due to Alzheimer disease: a pilot study
Van Bogaert, Peter,
Van Grinsven, Regine,
Tolson, Debbie,
Wouters, Kristien,
Engelborghs, Sebastiaan,
Van der Mussele, Stefan
Objective: To examine effects of individual thematically-based reminiscence sessions based on the SolCos model for older adults with dementia because of Alzheimer disease (AD) as a pilot study.; Background: Reminiscence activities are popular within nursing homes and generally considered to be enjoyable and helpful, however, there is a paucity of robust data demonstrating therapeutic impact. […]
Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer’s Disease: the MEMAGE study
Gareri, Pietro,
Putignano, Daria,
Castagna, Alberto,
Cotroneo, Antonino Maria,
De Palo, Grazia,
Fabbo, Andrea,
Forgione, Luigi,
Giacummo, Attilio,
Lacava, Roberto,
Marino, Saverio,
Simone, Maurizio,
Zurlo, Amedeo,
Putignano, Salvatore
Background: Combined therapy of memantine and acetylcholinesterase inhibitors (AChEIs) in patients with Alzheimer’s disease (AD) may be associated with higher benefits than either monotherapy.; Objective: This retrospective multicentric study conducted in seven Italian Ambulatory Centers for Dementia assessed the efficacy and safety of memantine 20 mg/day administered for 6 months in addition to an AChEI […]
“Dementia-friendly hospitals: care not crisis”: an educational program designed to improve the care of the hospitalized patient with dementia
Galvin, James E.,
Kuntemeier, Barbara,
Al-Hammadi, Noor,
Germino, Jessica,
Murphy-White, Maggie,
McGillick, Janis
Background: Approximately 3.2 million hospital stays annually involve a person with dementia, leading to higher costs, longer lengths of stay, and poorer outcomes. Older adults with dementia are vulnerable when hospitals are unable to meet their special needs.; Methods: We developed, implemented, and evaluated a training program for 540 individuals at 4 community hospitals. Pretest, […]
Cognitive functions in a patient with Parkinson-dementia syndrome undergoing deep brain stimulation
Freund, Hans-Joachim,
Kuhn, Jens,
Lenartz, Doris,
Mai, Jürgen K.,
Schnell, Thomas,
Klosterkoetter, Joachim,
Sturm, Volker
Background: Dementia represents one of the most challenging health problems. Despite intense research, available therapies have thus far only achieved modest results. Deep brain stimulation (DBS) is an effective treatment option for some movement disorders and is under study for psychiatric applications. Recently, diencephalic DBS revealed selective effects on memory functions, another facet of subcortical […]
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer’s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
Dodel, Richard,
Rominger, Axel,
Bartenstein, Peter,
Barkhof, Frederik,
Blennow, Kaj,
Förster, Stefan,
Winter, Yaroslav,
Bach, Jan-Philipp,
Popp, Julius,
Alferink, Judith,
Wiltfang, Jens,
Buerger, Katharina,
Otto, Markus,
Antuono, Piero,
Jacoby, Michael,
Richter, Ralph,
Stevens, James,
Melamed, Isaac,
Goldstein, Jerome,
Haag, Stefan,
Wietek, Stefan,
Farlow, Martin,
Jessen, Frank
Background: Three small trials suggest that intravenous immunoglobulin can affect biomarkers and symptoms of mild-to-moderate Alzheimer’s disease. We tested the safety, effective dose, and infusion interval of intravenous immunoglobulin in such patients.; Methods: We did a multicentre, placebo-controlled phase 2 trial at seven sites in the USA and five in Germany. Participants with probable Alzheimer’s […]